Market cap
₹341 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 73.33 | 0.00 | -56.25 | -25.42 | -1.80 |
| Net Profit | -890.55 | -49,675.00 | -13,637.50 | -25.38 | -347.87 |
| EPS | -890.81 | -50,507.69 | -13,867.31 | -769.90 | -347.87 |
| Book Value | -- | -- | 25.23 | 7.57 | 238.30 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-14 | Mar-13 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | 101.15 | -- | -- |
| Return on equity
| -0.29 | -0.82 | -6.25 | -0.27 | -0.35 |
| Return on Capital
| -0.28 | -0.25 | -- | -0.27 | -0.33 |
| Return on Assets
| -0.28 | -0.25 | -6.23 | -0.26 | -0.32 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
-0.27
|
-0.33
|
-0.24
|
-0.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-6.25
Lower than Peers by 17.10
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-6.25
|
-0.27
|
-0.35
|
-0.26
|
-0.42
|
|
Peer Median
|
10.86
|
--
|
--
|
--
|
--
|
ROA
-6.23
Lower than Peers by 12.97
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-6.23
|
-0.26
|
-0.32
|
-0.24
|
-0.25
|
|
Peer Median
|
6.74
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
12.69
|
--
|
--
|
--
|
--
|
Net Margin
101.15
Higher than Peers by 92.29
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
101.15
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.86
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.14
|
--
|
--
|
--
|
--
|
EBIT Growth
-56.25
Lower than Peers by 73.49
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-56.25
|
-0.28
|
-35.39
|
-16.76
|
-293.66
|
|
Peer Median
|
17.24
|
--
|
--
|
--
|
--
|
Net Profit Growth
-13,637.50
Lower than Peers by 13,654.35
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-13,637.50
|
0.08
|
-35.73
|
-16.84
|
-293.20
|
|
Peer Median
|
16.85
|
--
|
--
|
--
|
--
|
EPS Growth
-13,867.31
Lower than Peers by 13,877.91
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-13,867.31
|
21.43
|
-35.69
|
-16.72
|
87.29
|
|
Peer Median
|
10.60
|
--
|
--
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
59.47
|
-0.35
|
-0.26
|
2,405.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
0.01
|
--
|
0.13
|
--
|
|
Peer Median
|
0.04
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
0.01
|
--
|
0.13
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
287.81
Higher than Peers by 286.09
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
287.81
|
60.78
|
45.38
|
1.00
|
1.81
|
|
Peer Median
|
1.72
|
--
|
--
|
--
|
--
|
Quick Ratio
287.81
Higher than Peers by 286.64
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
287.81
|
60.78
|
45.38
|
1.00
|
3.17
|
|
Peer Median
|
1.17
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
-3,866.11
|
-260.17
|
-752.16
|
-1,664.71
|
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
25.79
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.67
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.90
|
--
|
--
|
--
|
--
|
Price / Book Value
8.97
Higher than Peers by 4.74
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
8.97
|
54.69
|
5.61
|
1.65
|
3.32
|
|
Peer Median
|
4.23
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
--
|
--
|
--
|
--
|
EV/EBITDA
-155.63
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
-155.63
|
--
|
-1,617.74
|
-695.60
|
-1,519.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
341
Lower than Peers by 7,271
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-14
|
Mar-13
|
Mar-12
|
Mar-11
|
|---|---|---|---|---|---|
|
Kappac Pharma
|
341
|
--
|
--
|
--
|
--
|
|
Peer Median
|
7,613
|
--
|
--
|
--
|
--
|